Aetna modified CPB 0070, its diabetes tests, programs, and supplies coverage policy, effective February 21, 2026. Here's what billing teams need to know.
Aetna, a CVS Health company, updated CPB 0070 to clarify medical necessity criteria across a broad range of diabetes-related services — from continuous glucose monitoring (CGM) devices billed under CPT 95249, 95250, and 95251 to self-management training under G0108 and G0109. The update also addresses coverage rules for implantable CGM sensors, GAD autoantibody testing, insulin delivery supplies, and diabetes prevention programs under 0403T. If your practice or DME supplier bills any of these codes to Aetna, this coverage policy update applies to you.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Diabetes Tests, Programs and Supplies |
| Policy Code | CPB 0070 |
| Change Type | Modified |
| Effective Date | February 21, 2026 |
| Impact Level | High |
| Specialties Affected | Endocrinology, Primary Care, DME Suppliers, Diabetes Education Programs, Clinical Labs |
| Key Action | Audit CGM billing workflows against updated long-term therapeutic use criteria before submitting claims dated on or after February 21, 2026 |
Aetna Diabetes Coverage Criteria and Medical Necessity Requirements 2026
CPB 0070 covers diabetes-related services across five main categories. Each has its own medical necessity criteria. Get the wrong one and you're looking at a claim denial.
Diabetes Self-Management Training
Aetna covers outpatient diabetes self-management training under G0108 (individual, per 30 minutes) and G0109 (group session, per 30 minutes) when three conditions are met. The program must be staffed by recognized healthcare professionals — physicians, registered dietitians, registered nurses, or registered pharmacists. It must be designed to educate the member about medically necessary diabetes self-care. And it must be ordered by the physician treating the member's diabetes, with a signed statement that the service is needed.
That third requirement — the signed physician statement — is the one that gets claims denied most often. Make sure your workflow captures that documentation before billing G0108 or G0109.
Diabetic Supplies
Standard diabetic supplies are covered under this policy. That includes blood glucose monitors (E0607), blood glucose test strips (A4253), lancets (A4259), alcohol swabs (A4245), insulin pens, needles and syringes (A4206–A4215), control solutions (A4256), and urine test tablets/strips (A4250). These are covered when medically necessary for members with diabetes — documentation of diagnosis is your foundation for reimbursement here.
Continuous Glucose Monitoring — Short-Term Diagnostic Use
For short-term CGM (72 hours to one week), billed under CPT 95249 and 95250, Aetna covers two specific situations. First, for members with diabetes who have hypoglycemia unawareness — or who have repeated hypoglycemia below 50 mg/dL and hyperglycemia above 150 mg/dL at the same time each day — unresponsive to conventional insulin dose adjustment. Second, for diagnosing primary islet cell hypertrophy (nesidioblastosis) or persistent hyperinsulinemic hypoglycemia of infancy in members with symptoms of recurrent hypoglycemia.
Aetna caps short-term diagnostic CGM at two monitoring periods per 12-month period. If you bill a third, expect a denial.
Continuous Glucose Monitoring — Long-Term Therapeutic Use
Long-term CGM (greater than one week) for devices like Dexcom, Eversense, Freestyle Libre, and Guardian — billed under CPT 95251 for analysis and interpretation, along with HCPCS codes A9276, A9277, A9278, and E2102 — requires specific criteria for initial approval. Check plan benefits for prior authorization requirements before submitting claims.
For initial approval, the member must have a diagnosis of diabetes mellitus (type 1 or type 2) and meet both of the following: they are using an intensive insulin regimen (defined as three or more injections per day or insulin pump therapy), and they either are under 18 years of age or are not meeting their glycemic target.
That "intensive insulin regimen" requirement is strict. Three or more injections per day — not two. Document this clearly in the medical record before billing.
GAD Autoantibody Testing
Aetna covers GAD autoantibody measurement (CPT 86341) in two situations. First, to distinguish type 1 from type 2 diabetes when the clinical history is ambiguous and the results will change patient management. Second, to diagnose stiff-person syndrome. Both are covered when medically necessary.
For everything else — including using anti-GAD testing to predict the onset of diabetes — Aetna considers the service experimental, investigational, or unproven. Don't bill it expecting coverage.
Jet Injectors as DME
Jet injectors are covered as durable medical equipment when the member or their caregiver is physically unable to use a conventional needle-syringe. That's the standard. If the reason for using a jet injector is preference or convenience, Aetna will not cover it. Document the functional limitation explicitly.
Aetna Diabetes Policy Exclusions and Non-Covered Indications
Several codes are specifically not covered under CPB 0070, and a few clinical applications are flagged as experimental or unproven.
CPT 0602U (KiHealth Diabetes Risk Test) is not covered under this policy. Don't bill it to Aetna expecting reimbursement.
CPT 0740T and 0741T — remote autonomous algorithm-based recommendation systems for insulin dose calculation and titration — are also not covered. These codes are excluded regardless of how the clinical team uses them.
CPT 81506 (Endocrinology type 2 diabetes, biochemical assays of seven analytes) is not covered for indications listed in this policy.
Anti-GAD antibody testing for predicting diabetes onset is explicitly experimental, investigational, or unproven. Any claim billed for that indication will be denied.
Jet injectors used for preference or convenience are also excluded. The policy is explicit: functional inability to use conventional needles is the only covered indication.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Diabetes self-management training — individual | Covered | G0108 | Physician order + signed statement required |
| Diabetes self-management training — group | Covered | G0109 | Physician order + signed statement required |
| Blood glucose monitors and supplies | Covered | E0607, A4253, A4259, A4245, A4250, A4256 | Diabetes diagnosis required |
| Short-term CGM — diagnostic (hypoglycemia unawareness or repeated hypo/hyperglycemia) | Covered | CPT 95249, 95250 | Max 2 periods per 12 months |
| Short-term CGM — diagnostic (nesidioblastosis or PHHI) | Covered | CPT 95249, 95250 | Max 2 periods per 12 months |
| Long-term CGM — therapeutic use | Covered with criteria | CPT 95251, A9276, A9277, A9278, E2102 | Check plan benefits for prior authorization requirements; intensive insulin regimen required |
| Implantable CGM sensor (Eversense) insertion | Covered with criteria | CPT 0446T, 0447T, 0448T; G0564, G0565 | Criteria apply |
| GAD autoantibody — type 1 vs. type 2 differentiation | Covered | CPT 86341 | Results must influence management |
| GAD autoantibody — stiff-person syndrome | Covered | CPT 86341 | See CPB 0340 |
| Jet injectors as DME | Covered | — | Physical inability to use needle-syringe required |
| Insulin and insulin pump supplies | Covered | J1811–J1817, S5550–S5552, A4230, A4231, E0784 | Medically necessary use |
| Diabetes prevention program | Covered with criteria | CPT 0403T | Standardized program criteria apply |
| Medical nutrition therapy | Related — check plan | CPT 97802, 97803, 97804 | Listed as related codes |
| HbA1c testing | Related — check plan | CPT 83036, 83037 | Listed as related codes |
| Anti-GAD antibody testing for diabetes risk prediction | Experimental / Not Covered | CPT 86341 | Explicitly unproven per policy |
| KiHealth Diabetes Risk Test | Not Covered | CPT 0602U | Excluded per CPB 0070 |
| Remote autonomous insulin dosing algorithm | Not Covered | CPT 0740T, 0741T | Excluded per CPB 0070 |
| Type 2 diabetes biochemical assay panel | Not Covered | CPT 81506 | Excluded per CPB 0070 |
| Jet injectors for preference or convenience | Not Covered | — | Explicitly excluded |
Aetna Diabetes Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your long-term CGM workflow before billing any claims dated on or after February 21, 2026. Confirm that every CGM claim for A9276, A9277, A9278, E2102, or CPT 95251 documents an intensive insulin regimen (3+ injections per day or insulin pump therapy). Check plan benefits for prior authorization requirements before submitting. |
| 2 | Pull all diabetes self-management training claims for G0108 and G0109 and verify physician order documentation. The signed physician statement is required — not optional. If your intake process doesn't capture it, fix that now. |
| 3 | Remove CPT 0602U, 0740T, and 0741T from any Aetna charge master or order sets tied to diabetes care. These codes are explicitly not covered under CPB 0070. Billing them wastes time and triggers denials. |
| 4 | Update your diabetes diagnosis billing guidelines to flag anti-GAD testing (CPT 86341) by indication. Covered for type differentiation and stiff-person syndrome — not covered for diabetes risk prediction. Your coders need to know the distinction, because the code is the same either way. |
| 5 | Review your jet injector DME claims. If any recent claims for jet injectors document "patient preference" as the reason, flag those for review. The policy is clear: physical inability to use conventional needles is the only covered path. |
| 6 | Check your short-term CGM utilization tracking. Aetna allows no more than two short-term diagnostic CGM periods in a 12-month rolling window. If your system doesn't track prior periods per patient, a third claim will be denied on frequency grounds. |
| 7 | For implantable CGM sensors (Eversense), confirm which HCPCS codes your MAC accepts. The policy references G0564 and G0565 for the 365-day sensor alongside 0446T, 0447T, and 0448T. Code selection depends on the payer's adjudication path. If you're unsure how Aetna wants these billed, talk to your billing consultant before submitting. |
CPT and HCPCS Codes for Diabetes Supplies and Testing Under CPB 0070
ICD-10-CM codes applicable to this policy are available in the full CPB 0070 document. The 143 ICD-10 codes referenced in this policy were not fully available for review; consult the source policy for the complete list.
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 0403T | CPT | Preventive behavior change, intensive program for prevention of diabetes using a standardized diabetes prevention program |
| 0446T | CPT | Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor |
| 0447T | CPT | Removal of implantable interstitial glucose sensor from subcutaneous pocket via incision |
| 0448T | CPT | Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different site |
| 82947 | CPT | Glucose; quantitative, blood (except reagent strip) |
| 82948 | CPT | Glucose; blood, reagent strip |
| 82950 | CPT | Glucose; post glucose dose (includes glucose) |
| 82962 | CPT | Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use |
| 83519 | CPT | Immunoassay, analyte, quantitative; by radiopharmaceutical technique |
| 86341 | CPT | Islet cell antibody |
| 95249 | CPT | Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor — short-term |
| 95250 | CPT | Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor — extended |
| 95251 | CPT | Ambulatory CGM — analysis, interpretation, and report |
Not Covered / Experimental CPT Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 0602U | CPT | KiHealth Diabetes Risk Test | Not covered for indications listed in CPB 0070 |
| 0740T | CPT | Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration | Not covered for indications listed in CPB 0070 |
| 0741T | CPT | Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration | Not covered for indications listed in CPB 0070 |
| 81506 | CPT | Endocrinology (type 2 diabetes), biochemical assays of seven analytes | Not covered for indications listed in CPB 0070 |
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| A4206 | HCPCS | Syringe with needle, sterile 1 cc or less, each |
| A4207 | HCPCS | Syringe with needle, sterile 2 cc, each |
| A4208 | HCPCS | Syringe with needle, sterile 3 cc, each |
| A4209 | HCPCS | Syringe with needle, sterile 5 cc or greater, each |
| A4211 | HCPCS | Supplies for self-administered injections |
| A4212 | HCPCS | Non-coring needle or stylet with or without catheter |
| A4213 | HCPCS | Syringe, sterile, 20 cc or greater, each |
| A4215 | HCPCS | Needle, sterile, any size, each |
| A4221 | HCPCS | Supplies for maintenance of drug infusion catheter, per week |
| A4222 | HCPCS | Infusion supplies for external drug infusion pump, per cassette or bag |
| A4230 | HCPCS | Infusion set for external insulin pump, non-needle cannula type |
| A4231 | HCPCS | Infusion set for external insulin pump, needle type |
| A4232 | HCPCS | Syringe with needle for external insulin pump, sterile, 3cc |
| A4233 | HCPCS | Replacement battery, alkaline (other than J cell), for home blood glucose monitor |
| A4234 | HCPCS | Replacement battery, alkaline, J cell, for home blood glucose monitor |
| A4235 | HCPCS | Replacement battery, lithium, for home blood glucose monitor |
| A4236 | HCPCS | Replacement battery, silver oxide, for home blood glucose monitor |
| A4238 | HCPCS | Supply allowance for adjunctive continuous glucose monitor (CGM), includes all supplies and accessories |
| A4244 | HCPCS | Alcohol or peroxide, per pint |
| A4245 | HCPCS | Alcohol wipes, per box |
| A4246 | HCPCS | Betadine or pHisoHex solution, per pint |
| A4247 | HCPCS | Betadine or iodine swabs/wipes, per box |
| A4250 | HCPCS | Urine test or reagent strips or tablets (100 tablets or strips) |
| A4252 | HCPCS | Blood ketone test or reagent strip, each |
| A4253 | HCPCS | Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips |
| A4255 | HCPCS | Platforms for home blood glucose monitor, 50 per box |
| A4256 | HCPCS | Normal, low, and high calibrator solution/chips |
| A4258 | HCPCS | Spring-powered device for lancet, each |
| A4259 | HCPCS | Lancets, per box of 100 |
| A4271 | HCPCS | Integrated lancing and blood sample testing cartridges for home blood glucose monitor, per month |
| A9274 | HCPCS | External ambulatory insulin delivery system, disposable, each |
| A9275 | HCPCS | Home glucose disposable monitor, includes test strips |
| E0607 | HCPCS | Home blood glucose monitor |
| E0784 | HCPCS | External ambulatory infusion pump, insulin |
| E2100 | HCPCS | Blood glucose monitor with integrated voice synthesizer |
| E2101 | HCPCS | Blood glucose monitor with integrated lancing/blood sample |
| E2102 | HCPCS | Adjunctive continuous glucose monitor or receiver |
| E2104 | HCPCS | Home blood glucose monitor for use with integrated lancing/blood sample testing cartridge |
| G0108 | HCPCS | Diabetes outpatient self-management training services, individual, per 30 minutes |
| G0109 | HCPCS | Diabetes outpatient self-management training services, group session, per 30 minutes |
| J1811 | HCPCS | Insulin (Fiasp) for administration through DME per 50 units |
| J1812 | HCPCS | Insulin (Fiasp), per 5 units |
| J1813 | HCPCS | Insulin (Lyumjev) for administration through DME per 50 units |
| J1814 | HCPCS | Insulin (Lyumjev), per 5 units |
| J1815 | HCPCS | Injection, insulin, per 5 units |
| J1817 | HCPCS | Insulin for administration through DME (insulin pump), per 50 units |
| S5550 | HCPCS | Insulin, rapid onset, 5 units |
| S5551 | HCPCS | Insulin, most rapid onset (Lispro or Aspart), 5 units |
| S5552 | HCPCS | Insulin, intermediate acting (NPH or LENTE), 5 units |
HCPCS Codes — Eversense E3 Implantable CGM (No Specific Code Designated)
| Code | Type | Description |
|---|---|---|
| A4239 | HCPCS | Supply allowance for non-adjunctive, non-implanted CGM, includes all supplies |
| A9276 | HCPCS | Sensor; invasive (subcutaneous), disposable, for use with interstitial CGM system |
| A9277 | HCPCS | Transmitter; external, for use with interstitial CGM system |
| A9278 | HCPCS | Receiver (monitor); external, for use with interstitial CGM system |
| E2103 | HCPCS | Non-adjunctive, non-implanted continuous glucose monitor or receiver |
| G0564 | HCPCS | Creation of subcutaneous pocket with insertion of 365-day implantable interstitial glucose sensor |
| G0565 | HCPCS | Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different site |
| S1030 | HCPCS | Continuous noninvasive glucose monitoring device, purchase |
| S1031 | HCPCS | Continuous noninvasive glucose monitoring device, rental, including sensor and replacement |
Get the Full Picture for CPT 95249
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.